The study was not sufficiently powered to evaluate the impact of our precision medicine concept on the risk of miscarriage or OHSS, nor can our results be extrapolated to the categories of women who were excluded, e.g. those with PCOS, endometriosis, etc. It remains to be seen whether these women, in whom the outcome of IVF may be negatively affected by the aforementioned pathological conditions, would benefit from a choice of FSH in relation to the N680S variants. This evidence concerns the gene BRD2 and spontaneous abortion.